LEADER 03773nam  22006255  450 
001 9910254509803321
005 20200703234721.0
010   $a3-319-27880-0
024 7 $a10.1007/978-3-319-27880-3
035   $a(CKB)3710000000627478
035   $a(EBL)4470896
035   $a(SSID)ssj0001654116
035   $a(PQKBManifestationID)16432924
035   $a(PQKBTitleCode)TC0001654116
035   $a(PQKBWorkID)14983058
035   $a(PQKB)11392261
035   $a(DE-He213)978-3-319-27880-3
035   $a(MiAaPQ)EBC4470896
035   $a(PPN)192774271
035   $a(EXLCZ)993710000000627478
100   $a20160331d2016      u|             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aOncological PET/CT with Histological Confirmation$b[electronic resource] /$fedited by Juliano Cerci, Stefano Fanti, Dominique Delbeke
205   $a1st ed. 2016.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2016.
215   $a1 online resource (100 p.)
300   $aDescription based upon print version of record.
311   $a3-319-27878-9 
320   $aIncludes bibliographical references and index.
327   $aPART I. Biopsy guided PET/CT: Principle of biopsy guided imaging.- FDG PET/CT to guide biopsy: methods.- FDG PET/CT to guide biopsy: type of acess.- PART II. FDG PET/CT in lymphoma: Need of biopsy in lymphoma.- FDG PET/CT to guide biopsy in lymphoma: results.- PART III. FDG PET/CT in pancreatic lesions:Need of biopsy in pancreatic lesions.- FDG PET/CT to guide biopsy in pancreatic lesions: results.- PART IV. FDG PEM in breast lessions: Need of biopsy in breast lesions.- FDG PEM to guide biopsy in breast lesions: results -- PART V. PET/CT and CNS malignancies: Need of biopsy in CNS malignancies -- FDG PET/CT to guide biopsy in CNS: results -- PART VI. PET/CT and prostate cancer -- Choline PET/CT to guide biopsy in prostate cancer diagnosis -- PART VII. FLT PET/CT in cancer diagnosis: FLT PET/CT in cancer diagnosis: results.
330   $aThis book reviews the important new field of PET/CT-guided biopsy, which is of potential value in optimizing the diagnostic yield of biopsies. The role of this technology is examined in a range of malignancies, including lymphoma, pancreatic, breast cancer and CNS malignancies. True positive and false positive cases are presented and discussed, and many aspects of PET and pathology are addressed. The book describes many case presentations illustrated with mostly 18F-FDG PET/CT images, but also other PET radiopharmaceuticals such as 18F-FLT. The three editors are expert nuclear medicine physicians from Europe and North and South America, and the range of experiences gained in using PET/CT across the globe is reflected in the book.
606   $aNuclear medicine
606   $aOncology  
606   $aPathology
606   $aNuclear Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H29048
606   $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160
606   $aPathology$3https://scigraph.springernature.com/ontologies/product-market-codes/H4800X
615  0$aNuclear medicine.
615  0$aOncology  .
615  0$aPathology.
615 14$aNuclear Medicine.
615 24$aOncology.
615 24$aPathology.
676   $a610
702   $aCerci$b Juliano$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aFanti$b Stefano$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aDelbeke$b Dominique$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910254509803321
996   $aOncological PET$92518515
997   $aUNINA